- Home
- CRTO vs GLPG Comparison
CRTO vs GLPG Comparison
Compare CRTO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- GLPG
- Stock Information
- Founded
- CRTO 2005
- GLPG 1999
- Country
- CRTO France
- GLPG Belgium
- Employees
- CRTO N/A
- GLPG N/A
- Industry
- CRTO Advertising
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CRTO Consumer Discretionary
- GLPG Health Care
- Exchange
- CRTO Nasdaq
- GLPG Nasdaq
- Market Cap
- CRTO 2.1B
- GLPG 1.8B
- IPO Year
- CRTO 2013
- GLPG 2005
- Fundamental
- Price
- CRTO $28.46
- GLPG $25.32
- Analyst Decision
- CRTO Buy
- GLPG Sell
- Analyst Count
- CRTO 11
- GLPG 4
- Target Price
- CRTO $44.70
- GLPG $25.33
- AVG Volume (30 Days)
- CRTO 452.8K
- GLPG 471.2K
- Earning Date
- CRTO 05-02-2025
- GLPG 04-23-2025
- Dividend Yield
- CRTO N/A
- GLPG N/A
- EPS Growth
- CRTO 107.32
- GLPG N/A
- EPS
- CRTO 2.44
- GLPG N/A
- Revenue
- CRTO $1,934,668,000.00
- GLPG $311,493,731.00
- Revenue This Year
- CRTO N/A
- GLPG N/A
- Revenue Next Year
- CRTO $7.92
- GLPG N/A
- P/E Ratio
- CRTO $11.64
- GLPG N/A
- Revenue Growth
- CRTO N/A
- GLPG 18.32
- 52 Week Low
- CRTO $26.67
- GLPG $22.36
- 52 Week High
- CRTO $49.93
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- CRTO 37.97
- GLPG 45.40
- Support Level
- CRTO $26.97
- GLPG $25.20
- Resistance Level
- CRTO $28.98
- GLPG $27.64
- Average True Range (ATR)
- CRTO 1.62
- GLPG 0.59
- MACD
- CRTO -0.30
- GLPG -0.09
- Stochastic Oscillator
- CRTO 21.23
- GLPG 23.93
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.